The CLCN5 antibody targets the chloride channel protein 5 (CLCN5), encoded by the *CLCN5* gene, which belongs to the CLC family of voltage-gated chloride channels and transporters. CLCN5 is primarily expressed in renal tubular epithelial cells, where it localizes to endosomal membranes and plays a critical role in regulating ion transport, endosomal acidification, and intracellular vesicle trafficking. Dysfunctional CLCN5 due to mutations is linked to X-linked recessive disorders such as Dent disease (type 1) and X-linked nephrolithiasis, characterized by low-molecular-weight proteinuria, hypercalciuria, and kidney stones.
CLCN5 antibodies are essential tools in biomedical research for detecting protein expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study CLCN5's role in renal physiology, disease mechanisms, and its potential involvement in cancer or metabolic disorders. These antibodies help validate *CLCN5* knockout models, assess tissue-specific expression, and investigate interactions with proteins involved in endocytic pathways. Commercial CLCN5 antibodies are typically raised in rabbits or mice, with specificity verified using knockout controls. Research utilizing these antibodies has advanced understanding of tubular disorders and may inform therapeutic strategies targeting ion transport defects.